A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/585 (2006.01) A61K 9/20 (2006.01) A61K 9/28 (2006.01) A61K 9/48 (2006.01) A61K 9/50 (2006.01) A61K 31/00 (2006.01) A61K 31/57 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2409437
A pharmaceutical composition is provided for administration to a subject mammal such as a human exhibiting a diurnal cycle of plasma aldosterone concentration, the composition comprising a delayed-release formulation of an aldosterone antagonist drug, e.g. , eplerenone, in a therapeutically effective amount. The delayed-release formulation, when administered about 6 hours to about 12 hours prior to the acrophase, results in a profile of plasma drug concentration that corresponds substantially to the diurnal cycle of plasma aldosterone concentration.
L'invention concerne une composition pharmaceutique destinée à être administrée à un sujet mammifère, tel qu'un humain, présentant un cycle diurne de concentration d'aldostérone dans le plasma, cette composition comprenant une formulation à action différée d'un médicament antagoniste de l'aldostérone, comme l'eplerenone, par exemple, en dose thérapeutiquement efficace. Cette formulation à action différée, lorsqu'elle est administrée 6 à 12 heures environ avant l'acrophase, permet d'obtenir une courbe de concentration de médicament dans le plasma correspondant sensiblement au cycle diurne de concentration d'aldostérone dans le plasma.
Garthwaite Susan M.
Mathur Leo K.
Osler Hoskin & Harcourt Llp
Pharmacia Corporation
LandOfFree
Aldosterone antagonist composition for release during... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aldosterone antagonist composition for release during..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aldosterone antagonist composition for release during... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2019742